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Abstract  Breast  cancer  consists  of  a  heterogeneous  group  of  tumors  with  different  features,
biology  and  treatments.  Cancer  stem  cells  (CSCs)  have  been  associated  with  an  aggressive
cellular  behavior,  resistance  to  chemotherapy  and  radiotherapy  in  many  types  of  neoplasms,  and
a strong  correlation  between  prominin-1  (CD133)  expression  in  cancer  stem  cells  from  different
types of  cancer  exist.  A  discussion  is  presented  on  recent  immunotherapeutic  strategies  that
target CD133  in  breast  CSCs.  Furthermore,  it  is  suggested  that  immunotherapy  targeting  CD133
breast CSCs  and/or  in  combination  with  other  current  treatments  result  in  a  better  outcome.
© 2016  Sociedad  Mexicana  de  Oncología.  Published  by  Masson  Doyma  México  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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CD133  en  células  de  cáncer  de  mama  y  en  células  madre  del  cáncer  como  otro  blanco
de  la  inmunoterapia
Resumen  La  neoplasia  de  mama  consiste  en  un  grupo  heterogéneo  de  tumores  con  carac-
terísticas, biología  y  tratamientos  diferentes.  Las  células  madre  del  cáncer  se  han  asociado
con un  comportamiento  agresivo  celular,  resistencia  a  la  quimioterapia  y  la  radioterapia  en
muchos tipos  de  tumores  y  existe  una  fuerte  correlación  en  la  expresión  de  prominin-1  (CD133)
en las  células  madre  de  cáncer  de  diferentes  tipos  de  cáncer.  En  este  artículo  se  discuten  las
estrategias recientes  de  inmunoterapia  que  se  dirigen  a  CD133  de  las  células  madre  cancerosas
de mama.  Además,  mostramos  que  la  inmunoterapia  dirigida  a  CD133  y/o  en  combinación  con
 podría  tener  un  mejor  resultado.
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Figure  1  CD133  cells  (breast  cancer  stem  cells  and  tumor
initiating  cells)  cause  malignant  while  progenitor  cells  despite
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Introduction
Despite  considerable  advances  in  early  detection,  diag-
nosis,  and  treatment,  breast  cancer  (BC)  is  the  most
frequently  diagnosed  cancer  in  women.1 To  date,  there  are
many  therapies  that  in  its  majority  are  non-speciﬁc  toward
cells  that  cause  cancer,  such  as  cancer  stem  cells.  Consider-
ing  that  cancer  cells  escape  to  our  immune  detection,  the
new  idea  is  to  try  to  use  the  weapons  of  the  immune  sys-
tem  against  these  cancer  cells.  Immunotherapy  is  a fast
advancing  methodology  involving  one  of  two  approaches:
(1)  Stimulating  our  own  immune  system  to  work  harder  or
smarter  to  attack  cancer  cells  and  (2)  Giving  you  immune
system  components,  such  as  man-made  immune  system
proteins.2 Breast  cancers  express  multiple  putative  tumor-
associated  antigens,  such  as  human  epidermal  growth  factor
receptor  2  (HER-2)  and  Mucin  1  (MUC1),  which  have  been
the  successful  focus  of  vaccine  development  over  the  past
decade,  translating  into  tumor-speciﬁc  immune  responses
and,  in  some  cases,  clinical  beneﬁt.  These  successes
observed  with  novel  immunotherapeutic  strategies,  such  as
immune  checkpoint  blockade  and  adoptive  T-cell  therapies
in  other  malignancies,  combined  with  other  strategies  have
the  potential  to  revolutionize  the  treatment  of  breast  can-
cer,  specially  targeting  cancer  stem  cells.1,3,4
CD133  or  prominin-1,  a  ﬁve  transmembrane  domain  cell-
surface  glycoprotein,  initially  associated  with  cholesterol
and  later  described  as  a  speciﬁc  biomarker  to  select  human
hematopoietic  progenitor  cells.  CD133  is  recognized  as  an
important  biomarker  to  identify  and  isolate  the  speciﬁc  cell
subpopulation  named  ‘‘cancer  stem  cells’’  in  many  types
of  neoplasms  including  breast  cancer.  CD133+ cells  have
stemness  properties  such  as  drug-resistance,  self-renewal,
differentiation  ability;  high  proliferation  (Fig.  1)  and  they
are  able  also  to  form  tumors  in  xenografts.  These  cells
with  CD133+ are  more  resistant  to  radiation  and  standard
chemotherapy  than  CD133(−) cells.5,6 In  this  review  we  dis-
cussed  CD133  in  breast  cancer  stem  cells  and  the  current
advances  as  a  target  of  immunotherapy.  Furthermore,  we
considered  the  possible  combination  of  other  anticancer
therapies  for  a  better  outcome.
CD133 in triple-negative breast cancer
Triple-negative  breast  cancer  (TNBC)  to  date  is  the  breast
neoplasia  with  highest  risk,  primarily  affecting  young
women.  Deﬁned  on  the  basis  of  immunohistochemistry,  neg-
ative  for  estrogen  receptor  (ER),  progesterone  receptor  (PR)
and  HER2  (member  of  the  epidermal  growth  factor  recep-
tor),  it  represent  approximately  20%  of  all  breast  tumors
with  a  considerable  clinical  relevance  due  to  be  resistant
to  conventional  chemotherapy,  poor  prognosis  and  a sig-
niﬁcantly  worse  clinical  outcome  than  other  cancers.7,8
Cantile  et  al.9 suggest  that  this  poor  prognosis  is  probably
due  to  a  nuclear  mislocalization  of  CD133,  which  normally
shows  membrane  localization  and  more  sporadically  cyto-
plasmic  localization.  Furthermore  as  it  is  known  that  surface
molecules,  when  are  moving  into  the  nucleus,  can  act
as  transcriptional  regulators  by  interfering  with  molecular
pathways  directly  connected  to  the  proliferation  and  differ-
entiation  of  tumor  cells.
A
o
a
hould  have  CD133  only  are  responsible  of  regeneration,  differ-
ntiation  and  maintenance.
Low  expression  of  CD133  characterizes  cells  with  larger
dhesion  area,  lower  proliferation  rate  and  reduced  migra-
ion  speed,  indicative  of  a  less  undifferentiated  phenotype.
onversely,  when  compared  with  high  CD133  expression,  the
ells  show  higher  invasive  capability  and  increased  expres-
ion  of  proteins  involved  in  metastasis  and  drug-resistance
f  breast  tumors.10,11 For  example,  expression  of  signaling
rotein  known  as  phospholipase  C2  (PLC-2)  correlates
ith  the  levels  of  CD133  and  has  a  role  in  inducing  the
D133high  cells  to  CD133low  cells  conversion.  This  mean
hat,  in  TNBC  cells,  the  de-regulation  of  PLC-2 is  respon-
ible  of  the  switch  from  an  early  to  a  mature  tumoral
henotype  also  by  reducing  the  expression  of  CD133.7 How-
ver,  Twist1  (transcription  factor),  which  induced  by  hypoxia
ccelerate  vasculogenic  mimicry  by  increasing  population  of
D133(+)  cells  is  responsible  for  the  regrowth  of  TNBCs.12
Epigenetic  changes  (DNA  methylation,  acetylation,  chro-
atin  modiﬁcation,  microRNA,  etc.)  also  have  a  correlation
ith  CD133  in  breast  cancer  stem  cells  (BCSCs)  in  TNBC,
mplicated  in  the  progression  and  recurrence.  Methylation
egulates  speciﬁc  BCSC-related  genes  [CD44,  CD133,  CD24,
SH1  (Musashi-1),  and  ALDH1],  epigenetic  proﬁle  that  can
dentify  aggressive  subtypes,  such  as  TNBC.13
he primo vascular system (PVS)
he  PVSs  consider  is  distributed  throughout  the  entire
ody.  The  system  is  composed  of  nodes  storing  many  small
ells  and  thin  vessels  branching  out  from  the  nodes.  Inside
he  vessel  there  are  multiple  sub  vessels.  The  PVS  is  found
n  and  on  most  organs,  including  the  brain,  and  interestingly
nside  some  lymph  and  blood  vessels.  The  PVS  is  normally
ifﬁcult  to  visualize  due  to  its  semitransparent  optical  prop-
rty  and  its  small  size.  The  diameter  of  primo  vessels  (PVs)
s  in  the  range  of  20--50  m  and  the  size  of  a  primo  node
PN),  100--1000  m.  Its  outermost  layer  is  more  porous  than
hat  of  blood  or  lymph  capillary  vessels,  and  the  nuclei  of
he  PVS  endothelial  cells  are  rod  shaped.  Inside  the  ﬂuid
f  PVS,  there  are  cells  presenting  stem  cell  markers  CD133,
ct4,  and  Nanog,  which  may  imply  that  this  system  has  a  role
n  regeneration  and  potential  relevance  to  breast  cancer.
ccording  to  results  from  an  animal  study  using  xenografts
f  various  cancer  types  (lung,  ovarian,  skin,  gastric  cancer,
nd  leukemia),  as  the  tumor  grows,  the  PVS  is  formed  in  a
igh  density  in  the  vicinity  of  the  tumor.  In  addition,  it  was
2 L.  Tume  et  al.
s
a
a
B
R
p
t
p
h
o
a
H
p
r
A
m
d
g
C
t
o
n
g
t
i
i
a
m
e
m
n
i
t
C
w
o
c
r
m
i
s
C
o
T
e
t
b
A
f
c
s
t
c
(
o
a
h
Primary culture
Meroclone Holoclone Paraclone
CSC
Transit-amplifying
cell
Differentiated
cell
Figure  2  Types  of  colony  derived  from  primary  culture  of
b
t
c
C
(
v
m
T
p
o
n
a
a
m
l
c
t
t
l
t
d
m
i
a
t
a
t
m
o
t
a
d
b
m
C
t
i
a
t
h
t4  
hown  that  PVs  connect  the  primary  and  secondary  tumors
nd  that  cancer  cells  were  transported  via  the  PVs  in  an
ctive  manner.2
reast cancer stem cells
ecently  has  emerged  the  concept  of  tumor  control
robability  (TCP),  formalism  derived  to  compare  various
reatment  regimens  of  radiation  therapy,  deﬁned  as  the
robability  that  given  a  prescribed  dose  of  radiation,  a  tumor
as  been  eradicated  or  controlled.  In  the  traditional  view
f  cancer,  all  cells  share  the  ability  to  divide  without  limit
nd  thus  have  the  potential  to  generate  a  malignant  tumor.
owever,  a  different  approach  arise  considering  a  sub-
opulation  of  cells,  the  so-called  cancer  stem  cells  (CSCs),
esponsible  for  the  initiation  and  maintenance  of  the  tumor.
 key  implication  of  the  CSC  hypothesis  is  that  these  cells
ust  be  eradicated  to  achieve  cures,  thus  is  possible  to
eﬁne  TCPs  as  the  probability  of  eradicating  CSCs  for  a
iven  dose  of  radiation.  A  proteins  expression  proﬁle,  such  as
D44high/CD24low/CD133(+),  is  often  used  as  a  biomarker
o  monitor  CSCs  enrichment.  However,  it  is  increasingly  rec-
gnized  that  not  all  cells  bearing  this  expression  proﬁle  are
ecessarily  CSCs,  and  in  particular  early  generations  of  pro-
enitor  cells  may  share  the  same  phenotype.14,15 We  need
o  take  in  account  that  CD133  expression  is  heterogeneous
n  different  carcinomas  but  was  strikingly  hyperexpressed
n  a  tubulolobular  variant  of  breast  cancer,  generally  with
 good  prognosis.16 Moreover,  CD133  along  with  epithelial
esenchymal  transition  proteins  and  N-cadherin  it  could  be
xplained  the  metastatic  events  in  breast  cancer.17,18
The  traditional  view  of  cancer  asserts  that  all  cells  in  a
alignant  tumor  are  clonogenic,  with  genetic  and  epige-
etic  differences.  The  existence  of  CSCs  has  been  ﬁrmly
dentiﬁed  in  leukaemia19 and  more  recently  in  many  solid
umors  including  breast  cancer.20 As  few  as  ∼200  cells  of  this
SCs  populations  are  capable  of  generate  tumors  in  animals,
hereas  the  bulk  of  the  tumor  population  is  tumorigenic
nly  when  implanted  at  high  numbers.  Like  their  normal
ounterparts,  the  cancer  stem  cells  have  the  ability  to  self-
enew,  driving  tumorigenicity  and  possibly  recurrence  and
etastasis,  and  have  the  ability  to  differentiate,  generat-
ng  the  heterogeneity  of  the  tumors.  In  these  cells,  cell
urface  and  transmembrane  proteins  such  as  CD44,  CD47,
D123,  EpCAM  (CD326),  CD133,  IGF  receptor  I,  and  proteins
f  the  Notch  and  Wnt  signaling  pathways  are  expressed.21,22
he  presence  of  many  of  these  proteins  determine  the  het-
rogeneity  of  CSCs,  a  critical  factor  for  use  customized
herapies.  Mukhopadhyay  et  al.23 studied  the  proportion  of
reast  cancer  cells  expressing  CD44(high)  CD24(low/neg),
LDH1(+),  CD49f  (high),  CD133(high),  and  CD34(high)  dif-
ered,  suggesting  heterogeneity.  However  CSCs  from  breast
ancer  expressed  only  CD133  in  high  proportion  in  compari-
on  to  the  other  proteins.
When  primary  cultures  of  normal  cells  are  cloned,  three
ypes  of  colony  grow,  called  holoclones  (derived  from  stem
ells),  meroclones  (transit-amplifying  cells)  and  paraclones
differentiated  cells)10 (Fig.  2).  Holoclone  cells  are  capable
f  forming  more  colonies  on  soft  agar  than  meroclone  cells
nd  paraclone  cells,  suggesting  that  holoclone  cells  had
igher  self-renew  potential  and  might  harbors  cancer  stem
C
o
ireast cancer  cells  depending  on  the  type  of  cell  from  which
he colony  is  cloned.
ells  (CSCs)  subpopulation.  Strikingly,  holoclone  display
D133(+)  phenotype  and  formed  vascular  malformations
VM).  In  addition,  holoclone  acquire  endothelial  cell  marker
ascular  endothelial-cadherin  expression  and  upregulated
atrix  metalloproteinase  (MMP)-2  and  MMP-9  expression.
he  subpopulation  with  holoclone  morphology,  CD133(+)
henotype  and  CSCs  characteristics  might  have  the  capacity
f  transdifferentiation  and  contributed  to  VM  in  triple
egative  breast  cancer.10,11
Current  models  of  stem  cell  biology  assume  that  normal
nd  neoplastic  stem  cells  reside  at  the  apices  of  hierarchies
nd  differentiate  into  non-stem  progeny  in  a  unidirectional
anner.  Chaffer  et  al.24 reported  a  subpopulation  of  basal-
ike  human  mammary  epithelial  cells  that  spontaneously
ould  converted  into  stem-like  cells.  Moreover,  oncogenic
ransformation  enhances  the  spontaneous  conversion,  so
hat  nonstem  cancer  cells  give  rise  to  cancer  stem  cell  (CSC)-
ike  cells  in  vitro  and  in  vivo.  These  ﬁndings  demonstrate
hat  normal  and  CSC-like  cells  can  arise  de  novo  from  more
ifferentiated  cell  types  and  that  hierarchical  models  of
ammary  stem  cell  biology  should  encompass  bidirectional
nterconversions  between  stem  and  nonstem  compartments.
Contradictory,  others  investigations  demonstrated  that
lso  CD133(−) cells  can  show  the  same  characteristics  of
hose  positive  for  CD133+.  Hence,  some  inconsistencies
mong  published  data  on  CD133  function  can  be  ascribed
o  different  causes  questioning  the  main  role  as  speciﬁc
arker  of  cancer  stem  cells.24 Indeed,  it  is  still  a  matter
f  debate  whether  CD133+ cells  truly  represent  the  ultimate
umorigenic  population.  However,  the  belief  that  CD133  may
ct  as  a  universal  marker  of  CSCs  has  been  met  with  a  high
egree  of  controversy  in  the  research  community.6 On  the
asis  of  the  involvement  of  CSCs  in  tumorigenesis  and  treat-
ent  resistance,  it  is  conceivable  that  only  eradication  of
SCs  can  lead  to  a  cancer  cure.24,25
Recently,  Shi  et  al.25 puriﬁed  exosomes  (family  of  bioac-
ive  vesicles  that  are  secreted  from  various  types  of  cell,
ncluding  tumor  cells)  in  4T1  mouse  breast  cancer  cells
nd  mouse  mammary  gland  epithelial  cells  with  pheno-
ype  CD133(+).  Exosomes  derived  from  breast  cancer  cells
ave  been  demonstrated  to  perform  important  functions  in
umor  progression  in  vitro  and  in  vivo.  Exosome  uptake  by
D133+  and  CD133-4T1  cells  indicates  that  the  proliferation
f  CD133+  cells  increase  and  the  apoptosis  is  suppressed.
Malignant  papillary  lesions  are  rare  malignant  tumors
n  the  breast.  Differentiation  between  benign  or  atypical
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and  malignant  papillary  lesions  is  difﬁcult.  Accordingly
to  Lin  et  al.26 while  the  expression  of  CD133  in  papillary
carcinomas  is  signiﬁcantly  lower  than  in  benign  and  atypical
papillomas,  CD133  expression  in  invasive  carcinoma  is
signiﬁcantly  higher  than  that  in  papillary  carcinomas.  In
inﬁltrating  ductal  carcinoma  (IDC)  tissues,  CD133,  CD44,
and  CD82  have  positive  relationship  in  this  carcinoma
especially  in  its  expression  in  CSCs.27
Targeting  breast  cancer  stem  cells  may  improve  cancer
therapy.  To  immunologically  target  CSC  phenotypes,  innate
immune  responses  to  CSCs  have  been  reported  using  Nat-
ural  killer  cells  and    T  cells.  To  target  CSC  speciﬁcally,
in  vitro  CSC-primed  T  cells,  CSC-based  dendritic  cell  vaccine
have  demonstrated  signiﬁcant  induction  of  anti-CSC  immu-
nity  both  in  vivo  in  immunocompetent  hosts  and  in  vitro  as
evident  by  CSC  reactivity  of  CSC  vaccine-primed  antibod-
ies  and  T  cells.28 In  addition,  CD133  along  with  ALDH,29
CD44  and  HER2  have  served  as  markers  to  isolate  CSCs
from  a  number  of  tumor  types  in  animal  models  and  human
tumors.  Therefore  targeting  CD133,  others  markers  and  ele-
ments  involved  in  the  CSC  niche  (myeloid-derived  suppressor
cells,  and  cytokines,  immune  checkpoint-PD1/PDL1)30 may
provide  additional  novel  strategies  to  enhance  the  immuno-
logical  targeting  of  CSCs.28,31
Diagnostic approach
Beyond  its  possible  correlation  with  stemness  of  tumor  cells,
CD133  is  considered  as  an  important  biomarker  in  breast
cancer,  since  it  correlates  with  tumor  size,  metastasis  and
clinical  stage,  and  it  could  be  used  in  diagnosis.  Breast  tumor
cells  have  often  already  been  disseminated  from  the  pri-
mary  site  and  can  be  detected  in  the  bone  marrow,  where
hematopoietic  progenitor  cells  (HPCs)  are  also  resident.32,33
In  ductal  breast  carcinomas,  epithelial  speciﬁc  antigen
(ESA),  one  of  the  breast  CSC  markers,  is  an  indicator  of
tumor  recurrence,  while  GPR30  is  associated  with  hormone
receptors.  Despite  the  correlation  between  GPR30  and  the
nuclear  estrogen  receptor,  the  expression  in  many  patients
is  dependent.34 However,  currently  CD133  and  Her-1  is
reported  as  important  markers  of  CSCs  for  the  prognosis  of
triple-negative  breast  cancer.  The  expression  of  CD133  with
Her-1  corresponded  to  tumor  size,  clinical  stage  and  lym-
phatic  metastasis,  but  not  to  age  and  histological  grade.35
Several  studies  have  suggested  that  Geminin  expression
is  a  marker  of  the  S/G2/M  phase  of  the  cell  cycle.36 Gem-
inin  is  frequently  overexpressed,  in  vivo,  in  a  variety  of
human  tumors  (kidney,  colon,  breast,  lung  cancer  and  lym-
phoma)  and  its  expression  rises  with  increasing  tumor  grade,
which  correlates  to  a  poor  prognosis.37 Therefore,  CD133
expression  is  associated  to  high  Geminin  expression.  This
association  between  the  expression  of  CD133  and  Geminin
will  indicate  the  molecular  stratiﬁcation  of  breast  tumors
and  in  particular  triple-negative  breast  cancers.38
In  addition  to  tests  of  self-renewal,  migration  and  vas-
culogenic  mimicry,  potentially  involved  in  generation  of
circulating  tumor  cells  (CTCs),  CD133  expression  in  CTCs  of
nometastatic  breast  cancer  (BC)  patients  is  another  option
for  diagnosis  in  early  stages  of  the  disease.  Nadal  et  al.39
isolated  CTCs  by  immunomagnetic  techniques  using  mag-
netic  beads.  They  identiﬁed  CTCs  positive  to  CD133  in  65%
i
H
a
t25
f  patients  at  baseline  and  47.8%  after  systemic  therapy.
efore  any  treatment,  CTCs  positive  to  CD133  are  more
requently  isolated  in  patients  with  luminal  BC  subtype.
o  statistically  signiﬁcant  differences  are  found  between
roportion  of,  CTCs  positive  to  CD133  and  BC  subtypes
fter  systemic  therapy,  implying  a  relative  enrichment  of
TCs  CD133(+)  in  triple  negative  and  HER2-ampliﬁed  tumors.
hile  CTCs  decreases  after  chemotherapy  when  analyz-
ng  the  population  CTCs  positive  to  CD133  is  enriched  in
ost-treatment  samples  in  non-luminal  BC  subtypes.  There-
ore  CD133  has  a  potential  role  as  a  promising  marker  of
hemoresistance  in  non-luminal  BC  patients.
The  pathologic  complete  response  (pCR)  rate  with
eoadjuvant  chemotherapy  remains  at  30%.  CD133  before
eoadjuvant  chemotherapy  might  be  a  useful  marker  for
redicting  the  effectiveness  of  this  care  and  recurrence  of
reast  cancer  after  chemotherapy.40 Oct-4  with  CD133  is  also
bserved  in  tumors  obtained  after  neoadjuvant  chemother-
py.  Moreover,  the  breast  CSCs  proﬁle  CD44(+)/CD24(−/low)
nd  CD133(+)  are  more  frequently  observed  in  hypoxic
egions  of  tumor,  whereas  ALDH-1(+)  cells  more  commonly
o-localized  to  tumors  with  high  microvessel  density.  Also,
he  CD326(−)CD45(−) fraction  of  patients  with  elevated
NAIL1  (involved  in  embryonic  mesoderm  formation)  and
EB1  (zinc  ﬁnger  E-box-binding  homeobox  1)  transcripts  had
 higher  percentage  of  ALDH(+)/CD133(+)  cells  in  their  blood
han  patients  with  normal  SNAIL1  and  ZEB1  expression.41
mmunotherapeutic strategy
any  common  cancer  therapies  such  as  chemotherapy  fail
o  eliminate  completely  CSCs,  leading  to  cancer  recurrence
nd  progression,  selective  targeting  of  CSCs  with  mono-
lonal  antibodies  represents  a  novel  therapeutic  strategy
gainst  cancer.  Monoclonal  antibodies  are  used  against  CSCs
roteins21 showing  efﬁcacy  reducing  cancer  in  mice,  and
ome  of  them  have  demonstrated  antitumor  activity  in
linical  settings.  For  example,  DDX3X  (DEAD/H  (Asp-Glu-Ala-
sp/His)  box  polypeptide  3,  X-linked)  is  suggested  as  an
mmunogenic  protein  preferentially  expressed  in  CD133(+)
reast  tumor  cells.  Vaccination  with  DDX3X  primed  speciﬁc
 cells,  resulting  in  protective  and  therapeutic  antitu-
or  immunity.  The  DDX3X-primed  CD4(+)  T  cells  produced
D133(+)  tumor-speciﬁc  IFN  and  IL-17  mediating  potent
ntitumor  therapeutic  efﬁcacy.42
Although  antibodies  against  CD133  are  commercially
vailable,  there  are  many  hurdles.  The  most  widely  used
nti-CD133  monoclonal  antibodies  recognize  what  was  ini-
ially  thought  to  be  poorly-deﬁned  glycosylated  epitopes,43
ut  more  recently  reported  to  be  non-glycosylated  epitopes
hat  are  lost  during  differentiation,  perhaps  due  to  epi-
ope  masking.44 In  either  case,  these  antibodies  do  not
etect  cells  expressing  certain  post-translationally  modi-
ed  CD133  epitopes  and  therefore  cannot  be  used  for  such
urposes.  Second,  commercially  available  anti-CD133  anti-
odies  that  target  an  unmodiﬁed  CD133  epitope  are  often
olyclonal.  Third,  most  of  the  currently  available  antibod-
es  are  only  suitable  for  use  in  limited  biological  assays.
owever,  Swaminathan  et  al.45 have  generated  a  novel
nti-CD133  monoclonal  antibody,  using  a  recombinant  pro-
ein  consisting  of  highly  immunogenic  amino  acid  residues
26  L.  Tume  et  al.
Tumor newly formed
Breast CSCs survival
Conventional non-
specifics therapies
Breast CSCs
(CD44, EpCAM, CD49f, CD133, ALDH-1 and CD34) Monoclonal
antibody for CD133
Antibody conjugated
with a drug
Growth diminished
Tumor erradication
CD133
Conventional
treatments
Figure  3  Breast  cancer  stem  cells  with  speciﬁcs  antigens:  CD44,  EpCAM  (epithelial  cell  adhesion  molecule),  CD49f,  ALDH-1
(aldehyde dehydrogenase),  CD34  and  CD133.  Conventional  non-speciﬁcs  therapies  allow  newly  tumor  formation  due  to  they  do  not
attack cells  responsible  for  tumor  survival  (CSCs).  Accordingly  to  literature  CD133  could  be  used  as  a  target  for  immunotherapy
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civing tumor  growth  diminished  and  possibly  upon  combine  co
ettings.
elected  from  the  native  CD133  protein  as  an  immunogenic
hat  speciﬁcally  recognizes  a  non-glycosylated  epitope  of
D133  and  is  useful  in  multiple  biological  assays.
To  eliminate  cells  with  phenotypic  markers  of  CSC-
ike,  Mine  et  al.46 characterized  cell  populations  with  the
reast  luminal  CSC  phenotype  [epithelial  speciﬁc  antigen(+)
ESA)  CD44(hi)  CD24(lo),  CD44(hi)  CD133(+),  and  CD133(+)
D24(lo)].  Once  characterized  it,  they  targeted  with  cyto-
oxic  T  lymphocytes  (CTL),  Numb  and  Notch,  under  the
ypothesis  that  both  antagonistic  proteins  prevent  the
etastases  in  patients  whose  tumors  are  resistant  to  con-
entional  treatments.
Recently  Huang  et  al.47 generated  an  anti-CD3/anti-
D133  bispeciﬁc  antibody  (BsAb)  and  bound  it  to  the
ytokine-induced  killer  (CIK)  cells  as  effector  cells  (BsAb-
IK)  to  target  CD133(high)  CSCs.  The  killing  of  CD133(high)
ancer  cells  by  the  BsAb-CIK  cells  was  signiﬁcantly  higher
han  the  killing  by  the  parental  CIK  or  by  CIK  cells  bound  with
nti-CD3  (CD3-CIK)  without  CD133  targeting.  Therefore,  a
imilar  investigation  could  be  made  in  breast  cancer  stem
ells  positive  to  CD133.
mmunotherapy in combination with other
herapeutic strategies
onoclonal  antibodies  are  very  speciﬁc  to  their  targets  and
ave  a  relatively  short  lifespan  inside  the  organism.  This
imits  the  undesirable  side  effects,  while  potentiating  the
nti-cancer  capabilities  of  the  therapy.  Unfortunately,  while
his  means  that  monoclonal  antibody  immunotherapy  is  con-
iderably  safer  than  other  forms  of  anti-cancer  therapy  --
amely  small  molecules  --  it  is  precisely  due  to  their  short
ifespan  that  the  efﬁcacy  of  the  treatment  is  limited.  This
rawback  might  be  overcome  through  the  simultaneously
se  of  monoclonal  antibodies  paired  up  with  chemotherapy48
Fig.  3).
t
e
ltional  treatments  we  could  obtain  better  outcomes  in  clinical
Relying  on  immunotherapy  studies  and  other  types
f  treatments,  the  combination  of  different  treatment
ould  be  successful  against  breast  cancer.  For  example,
he  chemotherapy  drug,  Paclitaxel  (microtubule-stabilizing
nticancer  agent)  is  used  for  the  treatment  of  cancer  but
ot  is  very  effective  in  decreasing  the  TIC  population.
owever  polymeric  nanoparticles  targeting  CD133  by  conju-
ating  an  anti-CD133  monoclonal  antibody  to  nanoparticles
CD133NPs)  loaded  with  paclitaxel  formulated  using  poly
d,  l  lactide-co-glycolide)  polymer  has  demonstrated  good
esults.  These  CD133-targeted  nanoparticles  are  efﬁciently
nternalized  by  cancer  cells,  which  abundantly  express
D133  (>9-fold  higher  uptake  than  non-targeted  control
anoparticles).  CD133NPs  also  decreased  effectively  the
mount  of  mammospheres  and  colonies  formed.49 Along  with
PB304,  a  novel  derivative  of  Sinenxan  A,  signiﬁcantly  might
ensitize  resistant  breast  cancer  cells  to  paclitaxel.50
Circulating  endothelial  cells  (CECs)  as  well  as  bone-
arrow-derived  endothelial  precursor  cells  (EPC)  play  an
mportant  role  in  neovascularization  and  tumors  growth.
ürstenberger  et  al.51 found  that  CECs  are  signiﬁcantly
levated  in  breast  cancer  patients  and  decreased  during
hemotherapy,  whereas  EPC  (CD34+/VEGFR-2+)  as  well  as
heir  progenitor  cell  population  CD133+/CD34+  and  the  pop-
lation  of  CD34+  stem  cells  increased.  Concomitantly  with
he  increase  of  progenitor  cells  an  increase  of  VEGF,  erythro-
oietin  and  angiopoietin-2  is  observed.  Chemotherapy  can
nly  reduce  the  amounts  of  mature  CEC,  probably  reﬂect-
ng  detached  cells  from  tumor  vessels,  whereas  the  EPC  and
heir  progenitors  are  mobilized  by  chemotherapy.  Since  this
obilization  of  EPC  may  contribute  to  tumor  neovascular-
zation  an  early  antiangiogenic  therapy  in  combination  with
hemotherapy  could  be  beneﬁcial  for  the  success  of  cancer
herapy.
Given  their  intrinsic  ability  to  home  to  tumor  sites,
ndothelial  progenitor  cells  (EPCs)  are  attractive  as  cel-
ular  vehicles  for  targeted  cancer  gene  therapy.  However,
 d
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sCD133  in  breast  cancer  cells  and  in  breast  cancer  stem  cells
collecting  sufﬁcient  EPCs  is  one  of  the  challenging  issues
critical  for  effective  clinical  translation  of  this  new
approach.  Purwanti  et  al.52 used  an  embryoid  body  for-
mation  method  to  derive  CD133+CD34+  EPCs  from  human
iPS  cells.  The  generated  EPCs  expressed  endothelial  mark-
ers  such  as  CD31,  Flk1,  and  vascular  endothelial-cadherin
without  expression  of  the  CD45  hematopoietic  marker.  After
intravenous  injection,  the  iPS  cell-derived  EPCs  migrated
toward  orthotopic  and  lung  metastatic  tumors  in  the  mouse
4T1  breast  cancer  model  but  did  not  promote  tumor  growth
and  metastasis.  The  systemic  injection  of  the  CD40  ligand-
expressing  EPCs  stimulated  the  secretion  of  both  tumor
necrosis  factor- and  interferon- and  increased  the  caspase
3/7  activity  in  the  lungs  with  metastatic  tumors,  leading  to
prolonged  survival  of  the  tumor  bearing  mice.
Sodium  butyrate  (NaBu)  is  regarded  as  a  potential
reagent  for  cancer  therapy.  40%  of  the  NaBu  resistant  cells
express  the  cancer  stem  cells  marker,  the  CD133,  whereas
only  10%  intact  cells  present  the  CD133  antigen.  Further-
more,  the  endogenous  expressing  c-MET  contributes  to  the
survival  of  cancer  stem  ion  from  the  treatment  of  NaBu.
The  CD133+  group  also  presents  a  higher  level  of  c-MET.
A  combination  treatment  of  MET  siRNA  and  NaBu  efﬁciently
prohibited  the  breast  cancer  progression,  and  the  incident
rate  of  the  tumor  decreased  to  18%.53
A  major  challenge  when  targeting  CD133-expressing
CSCs  is  to  prevent  depletion  of  the  normal  stem  cell
pool.  Photochemical  internalization  (PCI)  is  a  drug  deliv-
ery  technology  for  local,  light-controlled  cytosolic  release
of  drugs  entrapped  in  endosomes  and  lysosomes.  It  includes
drugs  that  are  too  large  or  too  hydrophilic  to  penetrate
the  cell  membrane.54 PCI  of  antibody--drug  conjugates  such
as  immunotoxins  provides  high  selectivity  against  speciﬁc
receptors  up-regulated  in  cancer  and  have  been  used  as
model  drugs  for  the  development  of  the  PCI  method  since
they  are  sequestered  in  endo/lysosomal  vesicles.  Immuno-
toxins  based  on  type  1  ribosome-inactivating  protein  toxins,
such  as  saporin  and  gelonin,  are  taken  up  by  receptor-
mediated  endocytosis.  Thus,  combining  CD133-targeting
therapeutics  with  the  PCI  technology,  where  light-activation
of  the  drug  is  constrained  to  the  tumor,  should  be  particu-
larly  beneﬁcial  as  this  minimizes  the  targeting  of  distant
normal  stem  cells  and  potentially  provides  a  wider  ther-
apeutic  window  of  the  CSC-targeting  drug.  Despite  PCI  of
CD133-targeting  toxins  may  be  used  as  a  minimal  invasive
strategy  in  the  treatment  of  sarcomas,  this  can  be  used  for
other  solid  tumors  expressing  CD133  as  breast  cancer.33
In  human  breast  tissues,  CD133  expression  is  lost  in
tumor-associated  endothelial  cells;  also  conversely,  CD49b
was  strongly  stained  in  the  tumors,  associated  vessels  and
ducts  but  was  weakly  stained  in  the  background  epithe-
lia.  q-PCR  analysis  revealed  that  CD44  and  PSCA  (prostate
stem  cell  antigen)  are  reduced  in  patients  with  poor  out-
come  (metastatic  disease  and  death  from  breast  cancer),
with  a  marked  reduction  in  ductal  carcinoma,  particu-
larly  with  metastasis  to  bone  although  these  did  not  reach
signiﬁcant  difference.  CD133  was  signiﬁcantly  reduced  in
patients  with  metastatic  disease  and  was  also  signiﬁcantly
reduced  in  patients  with  ductal  carcinoma/bone  metasta-
sis.  Conversely,  CD49F  was  increased  in  patients  with  a  poor
outcome  and  those  with  ductal  cancer  and  bone  metastases.
Such  differential  expression  may  play  a  part  in  breast  cancer
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isease  progression,  and  suggests  that  the  current  stem  cell
heory  may  not  hold  true  for  all  cancer  types.55
Ligand  of  CD133  has  been  identiﬁed  as  LS-7  (amino
cid  sequence:  LQNAPRS),  a  speciﬁc  binding  peptide  tar-
eting  mouse  CD133,  was  screened  and  identiﬁed  for
he  ﬁrst  time  by  phage-displayed  peptide  library  tech-
ology.  High-afﬁnity  binding  of  the  peptide  to  CD133  in
itro.  Confocal  microscopy  conﬁrmed  the  co-localization
f  LS-7  positive  cells  and  CD133-positive  cells.  Migration
nd  wound-healing  assays  showed  that  LS-7  signiﬁcantly
nhibited  the  migration  of  colon  and  breast  cancer  cells  in  a
oncentration-dependent  manner.  In  vivo  experiments  also
onﬁrmed  the  high  speciﬁcity  and  afﬁnity  of  LS-7  to  CD133.
T-PCR  and  Western  blot  showed  that  the  expressions  of  only
-Met  and  STAT3  decreased  obviously  in  colon  and  breast
ancer  cells  exposed  to  LS-7.56
Many  chemotherapeutic  regimens  trigger  cancer  cell
eath  while  inducing  dendritic  cell  maturation  and  subse-
uent  immune  responses.  However,  chemotherapy-induced
mmunogenic  cell  death  (ICD)  has  thus  far  been  restricted  to
elect  agents.  In  contrast,  several  chemotherapeutic  drugs
odulate  antitumor  immune  responses,  despite  not  induc-
ng  classic  ICD.  Docetaxel  treatment  of  tumor  cells  did  not
nduce  ATP  or  high-mobility  group  box  1  (HMGB1)  secre-
ion,  or  cell  death.  However,  calreticulin  (CRT)  exposure
as  observed  in  all  cell  lines  examined  after  chemotherapy
reatment.  Killing  by  carcinoembryonic  antigen  (CEA),  MUC-
,  or  PSA-speciﬁc  CD8(+)  CTLs  was  signiﬁcantly  enhanced
fter  docetaxel  treatment.  The  killing  is  associated  with
ncreases  in  components  of  antigen-processing  machinery,
nd  mediated  largely  by  CRT  membrane  translocation,  as
etermined  by  functional  knockdown  of  CRT,  PERK,  or  CRT-
locking  peptide.  In  the  treatment  docetaxel-resistant  cells
ith  phenotype  (MDR-1(+),  CD133(+))  were  found.  These
ells,  while  resistant  to  direct  cytostatic  effects  of  Doce-
axel,  are  not  resistant  to  the  chemomodulatory  effects
hat  resulted  in  enhancement  of  CTL  killing.  Here  appears
he  term  ‘‘immunogenic  modulation,’’  where  exposure  of
umor  cells  to  nonlethal/sublethal  doses  of  chemother-
py  alters  tumor  phenotype  to  render  the  tumor  more
ensitive  to  CTL  killing.  Docetaxel  alter  the  phenotype
f  human  tumor  cells  and  increase  their  susceptibility  to
D8+  CTL-mediated  killing.  These  observations  are  dis-
inct  and  complementary  to  ICD  and  highlight  a  mechanism
hereby  chemotherapy  can  be  used  in  combination  with
mmunotherapy.57
An  approach  different  to  antibodies  are  the  aptamers,  a
lass  of  small  nucleic  acid  ligands  that  are  composed  of  RNA
r  single-stranded  DNA  oligonucleotides  and  have  high  speci-
city  and  afﬁnity  for  their  targets.  Similar  to  antibodies,
ptamers  interact  with  their  targets  by  recognizing  a  speciﬁc
hree-dimensional  structure  and  are  thus  termed  ‘‘chemical
ntibodies.’’  In  contrast  to  protein  antibodies,  aptamers
ffer  unique  chemical  and  biological  characteristics  based
n  their  oligonucleotide  properties.58 Shigdar  et  al.59 iso-
ated  and  characterized  two  RNA  aptamers,  including  the
mallest  described  15  nucleotide  RNA  aptamers,  which
peciﬁcally  recognize  the  AC133  epitope  and  the  CD133
rotein  with  high  sensitivity.  As  well,  both  these  aptamers
how  superior  tumor  penetration  and  retention  when  com-
ared  to  the  AC133  antibody  in  a  3-D  tumor  sphere
odel.
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In  endocrinotherapy,  acquired  tamoxifen  (TAM)  resis-
ance  is  the  main  reason  for  failure  during  such  therapy.
reast  CSCs  played  an  important  role  in  TAM-induced  resis-
ance  during  breast  cancer  therapy.  Consistently,  qRT-PCR
evealed  that  TAM-resistant  (TAM-R)  MCF7  cells  expressed
ncreased  mRNA  levels  of  stem  cell  markers  including  SOX-
,  OCT-4,  and  CD133  also  these  cells  expressed  increased
RNA  levels  of  Snail,  vimentin,  and  N-cadherin  and
ecreased  levels  of  E-cadherin,  which  are  considered  as
MT  characteristics.11,60 Therefore  targeting  CD133  could  be
sed  for  the  successful  of  endocrinotherapy.61,62
Bostad  et  al.63 demonstrated  laser-controlled  targeting
f  CD133  in  vivo.  They  used  photochemical  internalization
PCI)  for  the  endosomal  escape  of  the  novel  CD133-
argeting  immunotoxin  AC133-saporin  (PCIAC133-saporin).
CI  employs  an  endocytic  vesicle-localizing  photosen-
itizer,  which  generates  reactive  oxygen  species  upon
ight-activation  causing  a  rupture  of  the  vesicle  membranes
nd  endosomal  escape  of  entrapped  drugs.  This  strategy
locked  cell  proliferation  and  induced  100%  inhibition  of
ell  viability  and  colony  forming  ability  at  the  highest  light
oses,  whereas  no  cytotoxicity  was  obtained  in  the  absence
f  light.  Efﬁcient  PCI-based  CD133-targeting  was  in  addition
emonstrated  in  the  stem-cell-like,  triple  negative  breast
ancer  cell  line  MDA-MB-231  and  in  the  aggressive  malignant
elanoma  cell  line  FEMX-1,  whereas  no  enhanced  target-
ng  was  obtained  in  the  CD133-negative  breast  cancer  cell
ine  MCF-7.  PCIAC133-saporin  induced  mainly  necrosis  and  a
inimal  apoptotic  response.
Accumulating  evidence  has  shown  inhibitory  effects  of
itamin  D  and  its  analogs  on  the  cancer  stem  cell  signaling
athways.64 A  study  published  by  Wahler  et  al.  and  So  &
uh  in  this  year  show  that  Vitamin  D  is  a  potential  preven-
ive/therapeutic  agent  against  CSCs  that  have  CD133  and
D44,  EpCAM,  CD49f,  CXCR4,  ALDH-1,  and  CD24.65
onclusion
D133  are  adequate  biomarker  of  breast  cancer  cells  and
reast  CSCs  that  might  be  useful  as  another  surrogate
arker  for  therapeutic  selection  and  monitoring  the  het-
rogeneity  of  cancer  and  as  a  target  of  immunotherapy  with
ntibodies.  Further  exploration  of  the  association  between
his  marker  and  speciﬁcs  stages  of  the  disease  is  needed  for
fﬁcient  anti-cancer  immunotherapy  using  CD133.  There-
ore,  conventional  treatments  along  with  immunotherapy
gainst  CD133  and  other  speciﬁcs  markers  of  CSCs  are  a
romising  treatment  option  in  efforts  to  eradicate  breast
ancer  in  the  clinical  settings.
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